We are live on ! Find out more
AVDL

Avadel Pharmaceuticals

Delisted

AVDL was delisted on the 11th of February, 2026.

56 hedge funds and large institutions have $211M invested in Avadel Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 7 increasing their positions, 15 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

717% more call options, than puts

Call options by funds: $29.6M | Put options by funds: $3.62M

300% more funds holding in top 10

Funds holding in top 10: 14 (+3)

213% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 8

52% more capital invested

Capital invested by funds: $139M → $211M (+$72.5M)

33% more funds holding

Funds holding: 4256 (+14)

22.5% more ownership

Funds ownership: 49.08%71.59% (+23%)

53% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 15

Holders
56
Holders Change
+14
Holders Change %
+33.33%
% of All Funds
1.23%
Holding in Top 10
4
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+300%
% of All Funds
0.09%
New
25
Increased
7
Reduced
15
Closed
8
Calls
$29.6M
Puts
$3.62M
Net Calls
+$26M
Net Calls Change
+$23.8M
Name Holding Trade Value Shares
Change
Change in
Stake
RI
1
RTW Investments
New York
$36.3M +$9.33M +1,215,136 +36%
ACA
2
Avoro Capital Advisors
New York
$34.7M +$33.5M +4,365,655 New
VC
3
Vivo Capital
California
$28.4M +$27.5M +3,575,424 New
ACP
4
Acuta Capital Partners
California
$20.9M +$8.06M +1,048,718 +65%
BIP
5
Brandes Investment Partners
California
$13M -$15.5M -2,013,110 -55%
CAC
6
Cowen and Company
New York
$10.8M +$11.7M +1,517,296 New
VA
7
VR Adviser
New York
$8.4M +$8.13M +1,057,827 New
Renaissance Technologies
8
Renaissance Technologies
New York
$7.19M +$398K +51,800 +6%
Invesco
9
Invesco
Georgia
$5.82M +$5.63M +733,012 New
Deutsche Bank
10
Deutsche Bank
Germany
$4.67M
TCM
11
Tekla Capital Management
Massachusetts
$4.5M -$1.91M -248,522 -31%
GJL
12
Gendell Jeffrey L
$4.39M -$4.56M -593,248 -52%
PVI
13
Pura Vida Investments
New York
$3.94M +$2.98M +387,660 +356%
DCM
14
Driehaus Capital Management
Illinois
$3.9M +$3.77M +490,878 New
Millennium Management
15
Millennium Management
New York
$3.61M -$1.34M -173,931 -28%
Ameriprise
16
Ameriprise
Minnesota
$3.46M -$341K -44,440 -9%
APM
17
Avidity Partners Management
Texas
$3.03M +$2.93M +382,000 New
GTC
18
Ghost Tree Capital
New York
$2.78M +$2.69M +350,000 New
Goldman Sachs
19
Goldman Sachs
New York
$1.52M +$1.47M +191,440 New
Morgan Stanley
20
Morgan Stanley
New York
$1.31M -$4.33M -563,701 -77%
ACM
21
Arlington Capital Management
Illinois
$920K +$890K +115,902 New
B
22
Bailard
California
$715K +$691K +90,000 New
ECM
23
Endurant Capital Management
California
$696K +$673K +87,676 New
IC
24
Ikarian Capital
Texas
$652K +$631K +82,143 New
California Public Employees Retirement System
25
California Public Employees Retirement System
California
$611K -$47.6K -6,200 -7%

AVDL Hedge Fund Activity: Q1 2020 in Review

56 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q1 2020, worth a combined $211M — up 52% from $139M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new AVDL positions and 8 closed out — a net gain of 17 holders — while 7 added to existing stakes and 15 trimmed.

The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $33.5M. The largest seller was Brandes Investment Partners, cutting an estimated $15.5M.

  • 56 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q1 2020, up from 42 in Q4 2019.
  • Funds reported $211M of Avadel Pharmaceuticals stock for Q1 2020, up 52% quarter-over-quarter.
  • 25 funds opened new Avadel Pharmaceuticals positions in Q1 2020 and 8 closed out, a net change of +17 holders.
  • The largest Avadel Pharmaceuticals buyer in Q1 2020 was Avoro Capital Advisors, an estimated $33.5M added.
  • The largest Avadel Pharmaceuticals seller in Q1 2020 was Brandes Investment Partners, an estimated $15.5M sold.

Based on aggregated 13F filings for Q1 2020.